Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients

Background  Lack of data on balancing bleeding and thrombosis risk causes uncertainty about restarting anticoagulants after major bleeding. Anticoagulant reversal trials offer prospectively gathered data after major bleeding with well-documented safety events and restarting behavior. Objectives  To...

Descripción completa

Detalles Bibliográficos
Autores principales: Milling, Truman J., King, Ben, Yue, Patrick, Middeldorp, Saskia, Beyer-Westendorf, Jan, Eikelboom, John W., Crowther, Mark, Xu, Lizhen, Verhamme, Peter, Siegal, Deborah M., Connolly, Stuart J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322590/
https://www.ncbi.nlm.nih.gov/pubmed/33634446
http://dx.doi.org/10.1055/a-1400-6159

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322590/
https://www.ncbi.nlm.nih.gov/pubmed/33634446
http://dx.doi.org/10.1055/a-1400-6159

Ejemplares similares